GHRHR and acute myeloid leukemia: The accumulated evidence indicates a susceptibility in AML, to MIA-602 mediated GHRH-R antagonism in a significant time- and dose-dependent manner by a mechanism of action that is distinct to commonly used drug-based targeted therapy regimens [27–31].